Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2017

Open Access 01-12-2017 | Erratum

Erratum to: RERG suppresses cell proliferation, migration and angiogenesis through ERK/NF-κB signaling pathway in nasopharyngeal carcinoma

Authors: Weilin Zhao, Ning Ma, Shumin Wang, Yingxi Mo, Zhe Zhang, Guangwu Huang, Kaoru Midorikawa, Yusuke Hiraku, Shinji Oikawa, Mariko Murata, Kazuhiko Takeuchi

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2017

Login to get access

Excerpt

Upon publication of the original article [1], it was noticed that Fig. 5 contained an error. The Fig. 5e (middle) for CD34 area fraction (%) data was erroneously included during the drafting of the manuscript. This has now been acknowledged and corrected in this erratum. The correct Fig. 5 is shown below.
Literature
1.
go back to reference Zhao W, Ma N, Wang S, Mo Y, Zhang Z, Huang G, Midorikawa K, Hiraku Y, Oikawa S, Murata M, Takeuchi K. RERG suppresses cell proliferation, migration and angiogenesis through ERK/NF-κB signaling pathway in nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2017;36(1):88.CrossRefPubMedPubMedCentral Zhao W, Ma N, Wang S, Mo Y, Zhang Z, Huang G, Midorikawa K, Hiraku Y, Oikawa S, Murata M, Takeuchi K. RERG suppresses cell proliferation, migration and angiogenesis through ERK/NF-κB signaling pathway in nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2017;36(1):88.CrossRefPubMedPubMedCentral
Metadata
Title
Erratum to: RERG suppresses cell proliferation, migration and angiogenesis through ERK/NF-κB signaling pathway in nasopharyngeal carcinoma
Authors
Weilin Zhao
Ning Ma
Shumin Wang
Yingxi Mo
Zhe Zhang
Guangwu Huang
Kaoru Midorikawa
Yusuke Hiraku
Shinji Oikawa
Mariko Murata
Kazuhiko Takeuchi
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2017
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-017-0565-6

Other articles of this Issue 1/2017

Journal of Experimental & Clinical Cancer Research 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine